Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:

TD Cowen 46

Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET.

The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET.

Leerink Global Healthcare Conference (Miami, FL) – presentation on Wednesday, March 11, 2026, at 9:20 am ET.

Stifel 2026 Virtual CNS Forum – fireside chat on Tuesday, March 17, 2026, at 9:30 am ET.

Interested parties may access the live and archived webcasts of the presentations and fireside chats under the “Investors” section of the company’s website.

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline is anchored by its epilepsy portfolio, including focal onset seizures and primary generalized tonic-clonic seizures, in addition to bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing/vestibular disorders.

Contact

Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics